TDOC Teladoc Health, Inc.
Services-Offices & Clinics of Doctors of Medicine · NYSE · SEC CIK 1477449 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.4%
TTM net income YoY30.8%
TTM EPS YoY31.7%
Revenue 3-yr CAGR-1.5%
Net income 3-yr CAGR—
Margins
Gross margin68.6%
Operating margin-6.6%
Net margin-6.3%
FCF margin10.6%
EBITDA margin—
Returns
ROE-11.5%
ROA-5.5%
ROIC (approx.)-23.2%
Asset turnover0.87x
Leverage & solvency
Liabilities / assets53.3%
Debt / equity0.00x
Current ratio0.87x
Interest coverage-8.00x
Cash quality & payout
Operating cash flow / net income-1.73x
Accruals ratio-15.0%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.53B | $2.57B | $2.60B | $2.41B | $2.03B |
| Cost of revenue | $771.59M | $751.27M | $760.03M | $743.99M | $650.26M |
| Gross profit | $1.76B | $1.82B | $1.84B | $1.66B | $1.38B |
| R&D expense | $277.92M | $307.27M | $348.52M | $333.63M | $311.88M |
| SG&A expense | $431.89M | $435.49M | $464.66M | $449.86M | $438.01M |
| Operating income | -$262.95M | -$1.02B | -$248.55M | -$13.65B | -$265.63M |
| Interest expense | $19.71M | $23.80M | $22.28M | $21.94M | $81.14M |
| Pretax income | -$235.53M | -$993.65M | -$219.61M | -$13.66B | -$384.66M |
| Income tax | -$35.21M | $7.59M | $760,000 | -$3.81M | $44.14M |
| Net income | -$200.32M | -$1.00B | -$220.37M | -$13.66B | -$428.79M |
| EBITDA | — | — | — | -$13.40B | -$61.39M |
| EPS (basic) | -1.14 | -5.87 | -1.34 | -84.60 | -2.73 |
| EPS (diluted) | -1.14 | -5.87 | -1.34 | -84.60 | -2.73 |
| Weighted avg. shares (diluted) | 176.22M | 170.56M | 164.58M | 161.46M | 156.94M |
| Banking | |||||
| Net interest income | — | — | — | -$9.27M | -$80.36M |
| Balance sheet | |||||
| Cash & equivalents | $781.08M | $1.30B | $1.12B | $918.18M | $893.48M |
| Short-term investments | — | — | — | $0 | $2.54M |
| Receivables | $192.83M | $214.15M | $217.42M | $210.55M | $168.96M |
| Inventory | $38.20M | $38.14M | $29.51M | $56.34M | $73.08M |
| Current assets | $1.12B | $1.66B | $1.49B | $1.32B | $1.23B |
| PP&E, net | $26.97M | $29.49M | $32.03M | $29.64M | $27.23M |
| Goodwill | $283.19M | $283.19M | $1.07B | $1.07B | $14.50B |
| Intangibles | $1.30B | $1.43B | $1.68B | $1.84B | $1.91B |
| Total assets | $2.86B | $3.52B | $4.39B | $4.35B | $17.73B |
| Current liabilities | $404.74M | $941.53M | $420.62M | $399.77M | $331.01M |
| Short-term debt | — | — | — | — | $0 |
| Total liabilities | $1.47B | $2.03B | $2.07B | $2.04B | $1.69B |
| Shareholders' equity | $1.39B | $1.49B | $2.33B | $2.31B | $16.05B |
| Shares outstanding | 178.32M | 173.41M | 166.66M | 162.84M | 160.47M |
| Cash flow statement | |||||
| Operating cash flow | $294.36M | $293.68M | $350.02M | $189.29M | $193.99M |
| Capital expenditure | $8.89M | $10.79M | $11.46M | $16.48M | $8.53M |
| Free cash flow | $285.46M | $282.89M | $338.56M | $172.81M | $185.46M |
| Investing cash flow | -$266.00M | -$124.05M | -$156.35M | -$167.74M | -$72.98M |
| Financing cash flow | -$551.65M | $8.31M | $10.85M | $6.50M | $40.95M |
| Depreciation & amortization | — | — | — | $256.03M | $204.24M |
| Stock-based compensation | $80.41M | $145.95M | $201.55M | $217.85M | $302.59M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.